EE200000499A - Angiotensiin II antagonistliku toimega toimeainetprolongeeritult vabastav preparaat, selle valmistamise meetod ja kasutamine - Google Patents

Angiotensiin II antagonistliku toimega toimeainetprolongeeritult vabastav preparaat, selle valmistamise meetod ja kasutamine

Info

Publication number: EE200000499A
Authority: EE; Estonia
Prior art keywords: preparation; angiotensin; prolonged; antagonist activity; release preparation
Prior art date: 1998-03-04

Application number

EEP200000499A

Other languages

English (en)

Estonian (et)

Inventor

Igari Yasutaka

Saikawa Akira

Inada Yoshiyuki

Kamei Shigeru

Original Assignee

Takeda Chemical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-04

Filing date

1999-03-03

Publication date

2002-02-15

1999-03-03 Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.

2002-02-15 Publication of EE200000499A publication Critical patent/EE200000499A/xx

Links

229940123413 Angiotensin II antagonist Drugs 0.000 title 1
239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
230000000694 effects Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
230000002035 prolonged effect Effects 0.000 title 1
102000005862 Angiotensin II Human genes 0.000 abstract 2
101800000733 Angiotensin-2 Proteins 0.000 abstract 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 2
229950006323 angiotensin ii Drugs 0.000 abstract 2
230000003042 antagnostic effect Effects 0.000 abstract 2
229920002988 biodegradable polymer Polymers 0.000 abstract 1
239000004621 biodegradable polymer Substances 0.000 abstract 1
230000036772 blood pressure Effects 0.000 abstract 1
230000027288 circadian rhythm Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003405 delayed action preparation Substances 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EEP200000499A 1998-03-04 1999-03-03 Angiotensiin II antagonistliku toimega toimeainetprolongeeritult vabastav preparaat, selle valmistamise meetod ja kasutamine EE200000499A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP5236698		1998-03-04
PCT/JP1999/001011 WO1999044590A1 (en)	1998-03-04	1999-03-03	Sustained-release preparation for aii antagonist, production and use thereof

Publications (1)

Publication Number	Publication Date
EE200000499A true EE200000499A (et)	2002-02-15

Family

ID=12912818

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000499A EE200000499A (et)	1998-03-04	1999-03-03	Angiotensiin II antagonistliku toimega toimeainetprolongeeritult vabastav preparaat, selle valmistamise meetod ja kasutamine

Country Status (21)

Country	Link
US (2)	US6589547B1 (xx)
EP (1)	EP1058541B1 (xx)
KR (1)	KR20010086245A (xx)
CN (1)	CN1291888A (xx)
AT (1)	ATE258430T1 (xx)
AU (1)	AU2745199A (xx)
BR (1)	BR9908474A (xx)
CA (1)	CA2318446C (xx)
DE (1)	DE69914460T2 (xx)
EE (1)	EE200000499A (xx)
ES (1)	ES2214013T3 (xx)
HU (1)	HUP0101439A3 (xx)
ID (1)	ID25640A (xx)
IL (1)	IL137979A0 (xx)
LT (1)	LT4800B (xx)
LV (1)	LV12585B (xx)
NO (1)	NO20004350L (xx)
PL (1)	PL342684A1 (xx)
SK (1)	SK11902000A3 (xx)
WO (1)	WO1999044590A1 (xx)
ZA (1)	ZA991706B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9908474A (pt) *	1998-03-04	2000-12-05	Takeda Chemical Industries Ltd	Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
CZ301913B6 (cs)	1999-04-28	2010-07-28	Takeda Pharmaceutical Company Limited	Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
EP1216038B1 (en)	1999-08-30	2005-09-07	Aventis Pharma Deutschland GmbH	Ramipril for the prevention of cardiovascular events
PL356422A1 (en) *	2000-02-18	2004-06-28	Takeda Chemical Industries, Ltd.	Tnf-alpha inhibitors
AU2001232348A1 (en) *	2000-02-21	2001-08-27	Takeda Chemical Industries Ltd.	Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
US20030187038A1 (en) *	2000-08-25	2003-10-02	Yoshimi Imura	Fibrinogen-lowering agents
US20040102502A1 (en) *	2000-10-25	2004-05-27	Toshifumi Watanabe	Preventing/remedies for portal hypertension
US20040121008A1 (en) *	2001-03-16	2004-06-24	Keiko Shiraishi	Process for producing sustained release preparation
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
BRPI0105509B8 (pt) *	2001-11-05	2021-05-25	Univ Minas Gerais	formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
EP1444988A4 (en) *	2001-11-13	2007-04-25	Takeda Pharmaceutical	CANCER AGENT
EP1452176A4 (en) *	2001-12-03	2009-01-21	Takeda Pharmaceutical	AGENTS FOR IMPROVING THE STATE OF RESISTANCE OF INSULIN
US7407778B2 (en) *	2002-02-07	2008-08-05	Pettegrew Jay W	Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) *	2002-02-07	2010-04-20	Pettegrew Jay W	Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
CN100438911C (zh) *	2002-12-27	2008-12-03	武田药品工业株式会社	体重增加抑制剂
US20050038093A1 (en) *	2003-05-02	2005-02-17	Boehringer Ingelheim International Gmbh	Treating diabetic retinopathy with angiotensin II receptor blockers
ATE437884T1 (de) *	2003-05-29	2009-08-15	Jay W Pettegrew	Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US20060257842A1 (en) *	2003-05-29	2006-11-16	Pettegrew Jay W	Cryopreservation media and molecules
WO2005097109A1 (en) *	2004-04-01	2005-10-20	Daniel Batlle	Methods for achieving a protective ace2 expression level
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
BRPI0516246A (pt) *	2004-10-07	2008-08-26	Takeda Pharmaceutical	agente para a profilaxia ou tratamento de sìndrome metabólica, método para a profilaxia ou tratamento de sìndrome metabólica em um mamìfero, e, uso de ácido 2-etóxi-1-[ [2'-(5-oxo-2,5-diidro-1,2,4-oxadiazol-3-il) bifenil-4-il]metil] -1h-benzimidazol-7-carboxìlico ou um sal do mesmo ou uma pró-droga do mesmo em combinação com uma substáncia semelhante ao agonista de ppargama
KR20070074576A (ko) *	2004-10-29	2007-07-12	코와 가부시키가이샤	사구체 질환 치료제
WO2006087394A1 (fr) *	2005-02-21	2006-08-24	Flamel Technologies	Forme pharmaceutique orale de losartan
NZ562887A (en) *	2005-03-30	2010-10-29	Takeda Pharmaceutical	Benzimidazole derivative and use as angiotensin II antagonist
KR20080039510A (ko) *	2005-08-22	2008-05-07	알렘빅 리미티드	발사르탄 제조 방법
AU2007282400B2 (en) *	2006-08-10	2012-08-30	Takeda Pharmaceutical Company Limited	Pharmaceutical composition
EP1897537A1 (en) *	2006-09-04	2008-03-12	Novartis AG	Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) *	2006-09-04	2008-12-04	Novartis Ag	Composicion farmaceutica que comprende valsartan
EP1908469A1 (en)	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
NZ577281A (en)	2006-12-18	2011-12-22	Takeda Pharmaceutical	Sustained-release composition and method for producing the same
CN101011393B (zh) *	2007-02-16	2010-10-06	广州柏赛罗药业有限公司	厄贝沙坦胃内滞留型缓释药物组合物
AU2008235790B2 (en) *	2007-03-28	2013-06-06	Takeda Pharmaceutical Company Limited	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
EP2281557A4 (en) *	2008-04-29	2011-08-31	Hanall Biopharma Co Ltd	PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
NZ597049A (en)	2009-05-20	2014-01-31	Boehringer Ingelheim Vetmed	Pharmaceutical oral telmisartan solution
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2751907A (en) *	1953-09-18	1956-06-26	Bishop & Co Platinum Works J	Pellet injector
JPS5671074A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	Imidazole derivative
IE802177L (en)	1980-10-21	1981-05-12	Takeda Chemical Industries Ltd	Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja)	1982-03-16	1983-09-19	Takeda Chem Ind Ltd	４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US4820843A (en)	1987-05-22	1989-04-11	E. I. Du Pont De Nemours And Company	Tetrazole intermediates to antihypertensive compounds
CA1338238C (en)	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en)	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en)	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
US4898732A (en) *	1988-05-04	1990-02-06	The Clinipad Corporation	Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de)	1989-04-08	1991-02-28	Thomae Gmbh Dr K	Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en)	1989-05-23	1995-08-09	Zeneca Ltd	Azaindenes
DE69010076T2 (de) *	1989-05-25	1994-12-08	Takeda Chemical Industries Ltd	Transdermales therapeutisches Mittel.
EP0403158A3 (en)	1989-06-14	1991-12-18	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids
DE69025473T2 (de)	1989-06-30	1996-10-17	Du Pont	Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
CA2020073A1 (en)	1989-07-03	1991-01-04	Eric E. Allen	Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en)	1989-07-06	1991-07-10	Ciba-Geigy Ag	Pyrimidine derivatives
EP0409332A3 (en)	1989-07-19	1991-08-07	Merck & Co. Inc.	Substituted triazoles as angiotensin ii antagonists
US5225205A (en) *	1989-07-28	1993-07-06	Debiopharm S.A.	Pharmaceutical composition in the form of microparticles
ATE113281T1 (de)	1989-08-02	1994-11-15	Takeda Chemical Industries Ltd	Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en)	1989-12-22	1991-06-26	Takeda Chemical Industries, Ltd.	Fused imidazole derivatives, their production and use
DE69129998T2 (de)	1990-02-15	1998-12-24	Takeda Chemical Industries, Ltd., Osaka	Pyrimidindionderivate, deren Herstellung und Verwendung
CA2036618C (en) *	1990-02-22	2002-10-29	Akira Morimoto	Fused thiophene derivatives, their production and use
IL99246A0 (en) *	1990-09-10	1992-07-15	Abbott Lab	Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5171217A (en) *	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
TW274551B (xx)	1991-04-16	1996-04-21	Takeda Pharm Industry Co Ltd
JPH06510763A (ja) *	1991-08-19	1994-12-01	イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー	アンジオテンシン２受容体遮断イミダゾリノン誘導体
TW284688B (xx) *	1991-11-20	1996-09-01	Takeda Pharm Industry Co Ltd
US5656297A (en)	1992-03-12	1997-08-12	Alkermes Controlled Therapeutics, Incorporated	Modulated release from biocompatible polymers
GB2272899A (en) *	1992-11-30	1994-06-01	Du Pont Merck Pharma	Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
DE69330593T2 (de)	1992-12-22	2002-06-27	Takeda Chemical Industries, Ltd.	Heterocyclische Verbindungen mit Angiotensin-II-antagonistischer Wirkung und ihre Anwendung
US5288720A (en) *	1993-04-23	1994-02-22	American Cyanamid Company	Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
EP0797988B1 (en) *	1993-07-19	2009-01-14	Angiotech Pharmaceuticals, Inc.	Anti-angiogenic compositions and methods of use
JPH0789849A (ja)	1993-09-20	1995-04-04	Fujisawa Pharmaceut Co Ltd	徐放性製剤
DE69632684T2 (de) *	1995-06-27	2005-06-09	Takeda Pharmaceutical Co. Ltd.	Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
PT889880E (pt)	1996-03-29	2003-09-30	Smithkline Beecham Corp	Di-hidrato de eprosartano e um processo para a sua producao e formulacao
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US6201002B1 (en) *	1997-01-10	2001-03-13	Merck & Co., Inc.	Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) *	1997-04-11	1999-09-28	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating erectile dysfunction
US6306826B1 (en) *	1997-06-04	2001-10-23	The Regents Of The University Of California	Treatment of heart failure with growth hormone
DE19741635A1 (de) *	1997-09-22	1999-03-25	Hoechst Marion Roussel De Gmbh	Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
BR9908474A (pt) *	1998-03-04	2000-12-05	Takeda Chemical Industries Ltd	Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica

1999
- 1999-03-03 BR BR9908474-0A patent/BR9908474A/pt not_active IP Right Cessation
- 1999-03-03 ZA ZA9901706A patent/ZA991706B/xx unknown
- 1999-03-03 IL IL13797999A patent/IL137979A0/xx unknown
- 1999-03-03 EP EP99907846A patent/EP1058541B1/en not_active Expired - Lifetime
- 1999-03-03 CA CA002318446A patent/CA2318446C/en not_active Expired - Fee Related
- 1999-03-03 EE EEP200000499A patent/EE200000499A/xx unknown
- 1999-03-03 DE DE69914460T patent/DE69914460T2/de not_active Expired - Lifetime
- 1999-03-03 ES ES99907846T patent/ES2214013T3/es not_active Expired - Lifetime
- 1999-03-03 PL PL99342684A patent/PL342684A1/xx unknown
- 1999-03-03 SK SK1190-2000A patent/SK11902000A3/sk unknown
- 1999-03-03 HU HU0101439A patent/HUP0101439A3/hu unknown
- 1999-03-03 CN CN99803444A patent/CN1291888A/zh active Pending
- 1999-03-03 AT AT99907846T patent/ATE258430T1/de not_active IP Right Cessation
- 1999-03-03 ID IDW20001680A patent/ID25640A/id unknown
- 1999-03-03 KR KR1020007008919A patent/KR20010086245A/ko not_active IP Right Cessation
- 1999-03-03 WO PCT/JP1999/001011 patent/WO1999044590A1/en not_active Application Discontinuation
- 1999-03-03 AU AU27451/99A patent/AU2745199A/en not_active Abandoned
- 1999-03-09 US US09/601,986 patent/US6589547B1/en not_active Expired - Fee Related
2000
- 2000-08-16 LV LVP-00-110A patent/LV12585B/en unknown
- 2000-08-31 LT LT2000082A patent/LT4800B/lt not_active IP Right Cessation
- 2000-09-01 NO NO20004350A patent/NO20004350L/no unknown
2003
- 2003-05-22 US US10/443,308 patent/US7294344B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1058541A1 (en)	2000-12-13
HUP0101439A2 (hu)	2001-10-28
ID25640A (id)	2000-10-19
DE69914460D1 (de)	2004-03-04
US6589547B1 (en)	2003-07-08
HUP0101439A3 (en)	2002-09-30
CN1291888A (zh)	2001-04-18
LV12585B (en)	2001-03-20
EP1058541B1 (en)	2004-01-28
CA2318446C (en)	2008-09-23
WO1999044590A1 (en)	1999-09-10
LV12585A (en)	2000-12-20
LT4800B (lt)	2001-06-25
US7294344B2 (en)	2007-11-13
NO20004350D0 (no)	2000-09-01
ZA991706B (en)	2000-10-03
DE69914460T2 (de)	2004-10-28
KR20010086245A (ko)	2001-09-10
BR9908474A (pt)	2000-12-05
ATE258430T1 (de)	2004-02-15
US20030198676A1 (en)	2003-10-23
SK11902000A3 (sk)	2001-02-12
IL137979A0 (en)	2001-10-31
LT2000082A (en)	2001-03-26
AU2745199A (en)	1999-09-20
PL342684A1 (en)	2001-07-02
ES2214013T3 (es)	2004-09-01
NO20004350L (no)	2000-10-03
CA2318446A1 (en)	1999-09-10

Publication	Publication Date	Title
EE200000499A (et)	2002-02-15	Angiotensiin II antagonistliku toimega toimeainetprolongeeritult vabastav preparaat, selle valmistamise meetod ja kasutamine
DE69926806D1 (de)	2005-09-22	N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de)	2005-09-29	N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
CY1115869T1 (el)	2017-01-25	Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη
DK1288223T3 (da)	2005-03-29	Terapeutiske peptidderivater
BR0110028A (pt)	2003-06-03	Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica
EA200301165A1 (ru)	2004-06-24	Лекарственное средство на основе оксикодона
BG66085B1 (bg)	2011-03-31	Фенилаланинови производни
CY1112395T1 (el)	2015-12-09	Δισκιο βαλσαρτανης
DK0976722T3 (da)	2009-05-04	Benzamidin-derivater
CY1118924T1 (el)	2018-01-10	Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
EA199700253A1 (ru)	1998-04-30	Производные нодулиспоровой кислоты
EA200200742A1 (ru)	2002-12-26	1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
EE05054B1 (et)	2008-08-15	5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
ATE295183T1 (de)	2005-05-15	Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
UA27713C2 (uk)	2000-10-16	Амідинові похідні бензолу, що мають гіпоглікемічну активність, та їх фармацевтично прийнятні солі
DE60028928D1 (de)	2006-08-03	Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
EA200100089A1 (ru)	2001-08-27	Предотвращение рецидива мигрени
EA200401137A1 (ru)	2005-04-28	Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE59910944D1 (de)	2004-12-02	Transdermales therapeutisches system zur anwendung von candesartan
EA200401617A1 (ru)	2005-06-30	Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
CY1106129T1 (el)	2011-06-08	Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
DE69821228D1 (de)	2004-02-26	Selektive mmp inhibitoren mit verringerten nebenwirkungen
FR2740337B1 (fr)	1997-11-21	Compositions pharmaceutiques stabilisees contenant un derive ayant une activite adrenergique
EA199800033A1 (ru)	1998-06-25	Антагонисты канала кальция